Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

@article{Drner2006InitialCT,
  title={Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus},
  author={Thomas D{\"o}rner and Joerg Kaufmann and William A. Wegener and Nick Teoh and David M. Goldenberg and Gerd-R. Burmester},
  journal={Arthritis Research & Therapy},
  year={2006},
  volume={8},
  pages={R74 - R74}
}
B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label, single-center study of 14 patients with moderately active SLE (total British Isles Lupus Assessment Group (BILAG) score 6 to 12) was conducted. Patients received 360 mg/m2 epratuzumab intravenously every 2 weeks for 4 doses with analgesic/antihistamine… CONTINUE READING
BETA

Citations

Publications citing this paper.

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

A 4-week course of rituximab plus cyclophosphamide in severe SLE: promising results in 9 patients who failed conventional immunosuppressive therapy

  • RF Van Vollenhoven, I Gunnarsson, E Welin-Henriksson, B Sundelin, SH Jacobson, L Kareskog
  • EULAR
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…